A double blind, placebo‐controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

SUMMARY. This is the first double-blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carriers. A fall of more than 90% in HBV DNA levels was noted in six of 11 evaluable patients treated with a 10 day course of oral famciclovir. Further studies with more prolonged therapy are ongoing.